You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

28 Results
Guidelines and Advice
Status: Archived
ID: HBOT
Jul 2013
Guidelines and Advice
Status: Archived
ID: 3-8-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 4-10
Aug 2013
Guidelines and Advice
Status: Archived
ID: 5-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 6-15
Dec 2013
Guidelines and Advice
Status: Archived
ID: 9-2
Nov 2013
Guidelines and Advice
Status: Archived
ID: 6-17
Nov 2013
Guidelines and Advice
Status: Archived
ID: 6-2
Version: 2
Aug 2013
Guidelines and Advice
Status: Archived
ID: 9-7
Mar 2013
Guidelines and Advice
Status: Archived
ID: 12-8
Version: 2
Jun 2013
Statistical Reports
Mar 2013
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
riTUXimab (subcut),
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide,
CISplatin,
cytarabine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2020

Pages